Twist Bioscience Corporation updated earnings guidance for the full fiscal year 2024. For the year, Total revenue is expected to be in the range of $288 million to $293 million, growth of 18% to 20%, Gross margin is expected to be approximately 40% to 41% for fiscal 2024, an increase across the range and Loss from operations before taxes of approximately $189 million to $194 million, an increase from $180 million to $188 million provided previously.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
45.82 USD | +4.10% | +7.66% | +23.96% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+23.96% | 2.56B | |
-1.62% | 90.85B | |
-0.92% | 39.02B | |
-10.70% | 33.46B | |
-19.74% | 14.51B | |
-5.99% | 13.22B | |
-11.42% | 11.65B | |
-47.31% | 10.57B | |
+6.52% | 9.23B | |
+137.06% | 7.71B |
- Stock Market
- Equities
- TWST Stock
- News Twist Bioscience Corporation
- Twist Bioscience Corporation Updates Earnings Guidance for the Full Fiscal Year 2024